Lyell Immunopharma, Inc. (LYEL) News
Filter LYEL News Items
LYEL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest LYEL News From Around the Web
Below are the latest news stories about LYELL IMMUNOPHARMA INC that investors may wish to consider to help them evaluate LYEL as an investment opportunity.
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of MelanomaSOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to LYL845, an investigational tumor infiltrating lymphocyte (TIL) product candidate for the treatment of patients with stage IIB-IV melanoma. “There remains a high unmet medi |
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023Extended funding of operations into 2027 by prioritizing investment in core clinical candidates and research platform value drivers as well as de-prioritizing selected early-stage research programsRemain on track to release initial clinical data from two clinical-stage product candidates in 2024Entered into proof-of-concept manufacturing collaboration with Cellares for CAR T cell product candidatePresented six abstracts at SITC highlighting innovations designed to shorten TIL manufacturing, new |
Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL ManufacturingSix presentations highlight innovations designed to shorten TIL manufacturing, new nonclinical data on LYL119, new technologies and clinical trials in progressSOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, is presenting new nonclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) |
Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 49% stakeKey Insights Institutions' substantial holdings in Lyell Immunopharma implies that they have significant influence over... |
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual MeetingPresentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials in progressSOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that six abstracts highlighting its broad pipeline of clinical and preclinical produ |
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle PlatformCellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Lyell Immunopharma (NASDAQ: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced Lyell will evaluate Cellares' automated manufacturing platform, the Cell Shuttle™, through Cellares' Technology Adoption Partnership (TAP) program. As part of the colla |
Lyell Immunopharma to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the following upcoming healthcare conferences: Morgan Stanley 21st Annual Global Healthcare Conference Monday, September 11, 4:55 p.m. ET H.C. Wainwright 25th Annual Global Investment Conferen |
Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging HigherShareholders in Lyell Immunopharma, Inc. ( NASDAQ:LYEL ) may be thrilled to learn that the analysts have just delivered... |
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023Cash, cash equivalents and marketable securities of $632.7 million as of June 30, 2023 support advancing multiple product candidates through key clinical milestonesRemain on track for initial clinical data from two lead product candidates in 2024Further strengthened executive leadership with appointment of Matt Lang, J.D., as Chief Business Officer SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company |
Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although... |